Geneyx was founded in 2018, with a mission to develop a clinical genetics data management platform that will address the challenges that hospitals and genetic labs were facing while analyzing and interpreting NGS genetic data. In 2020, we offered a comprehensive platform that was rapidly adopted by hospitals and labs around the world. Today, in 2023, the Geneyx Analysis platform is a leading solution for secondary and tertiary analysis in more than 35 countries, used by thousands of users with over 190K analyzed samples, taking a part in National Genome Projects, In leading academic research institutes.
Geneyx Analysis is an innovative platform for analyzing and interpreting germline and somatic sequencing data. This comprehensive tool tailors to all aspects of in-house bioinformatic pipelines but alleviates the associated complexities of staying up to date with current genomic information. Our team strives to provide a resource that significantly improves diagnostic yields and turnaround times, and our mission is to provide a platform that achieves a world without undiagnosed diseases. Below are some of the key features that contribute to this mission.
Workflow automation is valuable in high-throughput environments but is also important for obtaining accurate results by removing manual errors. Geneyx Analysis promotes automation using APIs and batches upload features, which enable secure communication with LIMS and EHR systems and large sample workflows. Geneyx Analysis can also be implemented at any stage in the bioinformatic pipeline, Fastq or VCF, and provides detailed audit trails to monitor every step of the NGS pipeline.
One distinct database valuable to whole genome sequencing analysis is the Geneyx Clinical Knowledgebase. This knowledgebase integrates machine learning to provide novel biomedical insights for gene-phenotype associations in coding and non-coding regions of the genome. Coupled with our innovative phenotype-driven interpretation algorithm, these features have led to important diagnoses in situations where exome sequencing has failed. As whole genome sequencing becomes the forefront in the clinical space, Geneyx Analysis will be a leading solution for interpretation.
Staying relevant on annotation sources is fundamental to correct diagnoses. To alleviate the complexities with updating annotations, Geneyx Analysis implements automated annotation and database updates. In addition to well-known annotations, literature sources and best-practice guidelines are also updated regularly. This ensures clinical geneticists and bioinformaticians are utilizing leading-edge information to provide accurate and complete diagnoses to their patients.
Following analysis and interpretation of NGS data are reporting. Most labs outsource reporting to third-party platforms, but this can be expensive, tedious, and time-consuming. Geneyx Analysis includes reporting capabilities within the software and allows reports to be fully customizable, including rendering in different languages.
Harnessing genetic data can be a valuable resource for identifying novel biomedical insights. Geneyx Analysis enables this through a warehouse environment to filter and search through all samples in an account to identify relevant cohorts and unique phenotype-gene associations.
In summary, Geneyx Analysis is a leading solution for NGS interpretation and evaluation. This platform aims to allow clinicians and geneticists to harness the genetic data within their current infrastructure and promote improved diagnosis and treatment options. Geneyx Analysis addresses all bioinformatic needs and has been shown to improve diagnostic yields and turnaround time. This technology is advancing the field of next generation sequencing and is advancing the field of precision medicine.
We’re always here for any questions, issues or brilliant ideas. Fill out the form below and a member of our team will be in touch.